Adds new sizes for containers aimed at large-volume auto-injectors and wearable devices.
Facility consolidates biosafety testing, analytical development, and cell bank manufacturing services into single building.
Tips on navigating outsourcing partnerships for start-ups.
Will enhance its ADC conjugation and purification clinical suite in Halle/Westfalen, Germany.
Adapting to the changing pharmaceutical landscape, key highlights for attendees, and looking ahead at strategic plans for CPHI.
Is designed to increase yield and productivity in upstream bioprocessing of gene therapy applications.
SK pharmteco will be the preferred manufacturing partner for Aavigen’s lead gene therapy product AVG-101 for the treatment of heart failure.
Will highlight new solutions for single-use bioprocessing, cell & gene therapies and more.
Plans several more product launches for the upcoming year.
Platform provides a versatile pre-filled and pre-loaded on-body solution suitable for highly viscous biologics.
Construction of new lab space at the company’s global headquarters in Craigavon considerably increases overall capacity.
The Vacaville, CA facility significantly extends Lonza’s capacity for mammalian manufacturing in the US.
Aims to enhance sterile manufacturing capabilities in the U.S.
Commits to aligning its operations and strategies with responsible business practices.
Will introduce fill-finish services for the RTU cartridge used in Maggie 5.0 autoinjectors.
Will highlight its EcoPositive range of low-impact, pharma-grade products.
Bridgeton, MO facility ready to provide injectable fill-finish capabilities.
New 150,000 sq.-ft. building will house two high-speed automated isolator syringe fill lines and a new high speed isolator vial line.
Recent campus expansion and investment in two additional packaging lines will support manufacture of forecasted volumes.
New 150,000 sq.-ft. building will house two high-speed automated isolator syringe fill lines and a new high speed isolator vial line.